MedTrace Logo

Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI

NCT02943369 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-12-27

No results posted yet for this study

Summary

Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery occlusion and subsequent myocardial infarction. Apart from mechanically opening the occluded artery with angioplasty, adjunctive antiplatelet treatment is of utmost importance. However, orally administered antiplatelet agents exhibit a delay in their onset of action in the setting of acute myocardial infarction and angioplasty is mostly performed without adequate platelet inhibition. Cangrelor is an intravenous antiplatelet agent which can provide almost immediate strong platelet inhibition. The investigators aim to compare a strategy of cangrelor administered on top of ticagrelor-an oral antiplatelet agent- vs ticagrelor alone, on their efficacy to inhibit platelet function in the early hours of an acute myocardial infarction.

Conditions

  • STEMI

Interventions

DRUG

Ticagrelor 180 mg loading dose

Ticagrelor 180 mg

DRUG

Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min

Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours

Sponsors & Collaborators

  • AHEPA University Hospital

    collaborator OTHER

  • University Hospital, Alexandroupolis

    collaborator OTHER

  • Attikon Hospital

    lead OTHER

Principal Investigators

  • Dimitrios Alexopoulos, MD · Attikon Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-28
Primary Completion
2017-11-26
Completion
2017-12-26

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943369 on ClinicalTrials.gov